Moomoo AIのまとめ
Cardio Diagnostics Holdings, Inc. reported its financial performance for the quarter ended June 30, 2024. The company saw a net loss of $1,287,995 for the quarter, a significant improvement from the $4,022,905 net loss in the same period the previous year. This reduction in net loss was primarily due to decreased general and administrative expenses and lower interest expenses. Revenue for the quarter was $7,870, up from $1,725 year-on-year, indicating some growth in the company's sales. Operating expenses totaled $1,290,330, with the largest contributor being general and administrative expenses at $1,220,477. Research and development costs were $7,280, and sales and marketing expenses were $57,779. The company's future plans include expanding its product offerings, increasing market reach, and pursuing potential strategic partnerships or acquisitions. Cardio Diagnostics Holdings, Inc. is focused on developing products for cardiovascular disease and associated co-morbidities, leveraging its AI-driven Integrated Genetic-Epigenetic Engine™. Despite the improved financial performance, the company acknowledges the need for additional equity financing to sustain operations beyond the next 12 months.
Cardio Diagnostics Holdings, Inc. reported its financial performance for the quarter ended June 30, 2024. The company saw a net loss of $1,287,995 for the quarter, a significant improvement from the $4,022,905 net loss in the same period the previous year. This reduction in net loss was primarily due to decreased general and administrative expenses and lower interest expenses. Revenue for the quarter was $7,870, up from $1,725 year-on-year, indicating some growth in the company's sales. Operating expenses totaled $1,290,330, with the largest contributor being general and administrative expenses at $1,220,477. Research and development costs were $7,280, and sales and marketing expenses were $57,779. The company's future plans include expanding its product offerings, increasing market reach, and pursuing potential strategic partnerships or acquisitions. Cardio Diagnostics Holdings, Inc. is focused on developing products for cardiovascular disease and associated co-morbidities, leveraging its AI-driven Integrated Genetic-Epigenetic Engine™. Despite the improved financial performance, the company acknowledges the need for additional equity financing to sustain operations beyond the next 12 months.
Cardio Diagnostics Holdings, Inc.は、2024年6月30日に終了した四半期の財務業績を発表しました。同社は、四半期に1,287,995ドルの純損失を計上しましたが、前年同期の4,022,905ドルの純損失から大幅に改善されました。純損失の減少は、一般および管理費用の減少と利息費用の低下に主に起因しています。四半期の売上高は7,870ドルで、前年同期比の1,725ドルから成長傾向であることを示しています。営業費用は1,290,330ドルであり、最大の貢献者は1,220,477ドルの一般および管理費用でした。研究開発費は7,280ドル、販売およびマーケティング費用は...すべて展開
Cardio Diagnostics Holdings, Inc.は、2024年6月30日に終了した四半期の財務業績を発表しました。同社は、四半期に1,287,995ドルの純損失を計上しましたが、前年同期の4,022,905ドルの純損失から大幅に改善されました。純損失の減少は、一般および管理費用の減少と利息費用の低下に主に起因しています。四半期の売上高は7,870ドルで、前年同期比の1,725ドルから成長傾向であることを示しています。営業費用は1,290,330ドルであり、最大の貢献者は1,220,477ドルの一般および管理費用でした。研究開発費は7,280ドル、販売およびマーケティング費用は57,779ドルでした。同社の将来の計画には、製品提供の拡大、市場の拡大、および潜在的な戦略的パートナーシップや買収に取り組むことが含まれます。Cardio Diagnostics Holdings, Inc.は、人工知能を活用したIntegrated Genetic-Epigenetic Engine™による心血管疾患および関連する合併症の製品開発に注力しています。改善された財務業績にもかかわらず、同社は次の12カ月以降の事業を維持するために追加の資本調達の必要性を認識しています。
役に立った
役に立たない